Answers, evidence, clarity

Novilora® is the registered U.S. product name for OnLife®, a nutritional supplement developed and produced in Italy. It is based on a patented combination of specific fatty acids and palmitoylethanolamide (PEA), and the formulation has been evaluated in published clinical research involving people experiencing symptoms associated with chemotherapy-induced peripheral neuropathy (CIPN).

Yes. Novilora® brings the established OnLife® product to customers in the United States under its registered U.S. name. Same formulation, same manufacturer, same published research.

No. Novilora® is a nutritional supplement and does not require a prescription. It is not intended to diagnose, treat, cure, or prevent any disease.

CIPN stands for chemotherapy-induced peripheral neuropathy. It may involve symptoms such as numbness, tingling, burning, discomfort, or sensitivity, often affecting the hands and feet. Anyone experiencing these symptoms should discuss them with a qualified healthcare professional.

Until now, U.S. customers generally had to order the product from Europe. After international shipping and currency conversion, the total cost could exceed $100. Novilora® is making the product available domestically for the first time.

Novilora® is produced in Italy by an established pharmaceutical and supplement manufacturer.

The initial U.S. inventory is arriving soon. Customers can reserve their orders now to be among the first to receive Novilora®.

Customers who are receiving cancer treatment, taking medications, pregnant or nursing, managing a medical condition, or considering a new supplement should consult their physician or another qualified healthcare professional before use.

Novilora's ingredients are formulated to support several aspects of nerve health: the structural integrity of nerve cells and myelin, cellular energy production, healthy inflammatory balance, and normal nerve signaling.

Loading phase: take 2 tablets twice a day (2 in the morning and 2 in the evening, with food) for at least 8–10 days. Do not stop after 3–4 days if you don't yet feel a change — Novilora needs this time to show its effect. Maintenance phase: continue with 1 tablet twice a day (morning and evening) for at least three months. Long-term support: consider a maintenance therapy of 1 tablet per day for an additional three months.

The published research evaluated a three-month period of consistent daily use. Plan on a full three-month course before judging results — after the initial 8–10 day loading phase — and then decide next steps with your healthcare provider.

Novilora is built around a patented combination of specific fatty acids and palmitoylethanolamide (PEA). A full ingredient list is printed on the package.

Novilora is designed for people experiencing symptoms such as pain, tingling, burning, or numbness — and for those seeking a proactive, science-informed approach to supporting nerve health. Talk to your healthcare provider about whether Novilora is right for you.

Novilora is generally compatible with other supplements, but you should consult your healthcare provider — especially if you take prescription medications or have a complex health history.

Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide produced by the body, particularly in response to stress or injury. It has been studied for its role in supporting healthy inflammatory balance and nerve cell function.

Fatty acids are essential building blocks of cell membranes, including the myelin sheath that insulates nerves. Specific fatty acids support the structural raw materials nerves need to function well.